Federal Clarity for Kratom Consumers Act
Key claim: The Federal Clarity for Kratom Consumers Act would require the FDA to hold a hearing and establish a task force on kratom health and safety while prohibiting the agency from regulating kratom more restrictively than food, dietary supplements, or dietary ingredients.
Abstract
(HR9634 · 117th Congress) Federal Clarity for Kratom Consumers Act This bill requires the Food and Drug Administration (FDA) to hold a hearing and establish a task force on the health and safety of products with kratom (an herbal substance that produces opioid- and stimulant-like effects). It also prohibits the FDA from regulating kratom products in a manner that is more restrictive as compared to regulations for food, dietary supplements, or dietary ingredients. Latest action (2022-12-20): Referred to the House Committee on Energy and Commerce.
Why this matters
The bill would set a statutory floor on how FDA can treat kratom — no stricter than food or dietary supplements — which would preserve consumer access to kratom products sold as supplements. It also forces a formal FDA hearing and interagency task force on kratom safety, potentially reshaping how federal agencies coordinate on a substance simultaneously targeted by DEA scheduling actions against its key alkaloids.